Haleon PLC (GB:HLN)
LSE:HLN
Want to see GB:HLN full AI Analyst Report?
Top Page
Haleon PLC
(LSE:HLN)
Select Model
Select Model
Rating:67Neutral
Price Target:
375.00 p
▲(4.57% Upside)
Action:DowngradedDate:02/26/26
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
Positive Factors
Consistent free cash flow generation
Haleon's steady OCF (~$2.1–2.3B) and FCF (~$1.7–2.0B) provide durable internal funding for reinvestment, debt reduction, buybacks and R&D. Reliable cash conversion supports strategic flexibility and lowers dependence on external financing over the medium term.
Negative Factors
Elevated leverage vs pre‑spin years
Although debt fell in 2025, leverage remains meaningfully above 2020–21 levels and assets have declined, reducing balance‑sheet headroom. Elevated leverage constrains capital allocation flexibility, increases interest and refinancing risk, and limits capacity for large M&A or cyclical shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent free cash flow generation
Haleon's steady OCF (~$2.1–2.3B) and FCF (~$1.7–2.0B) provide durable internal funding for reinvestment, debt reduction, buybacks and R&D. Reliable cash conversion supports strategic flexibility and lowers dependence on external financing over the medium term.
Read all positive factors
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£31.60B
Dividend Yield1.51%
Average Volume (3M)23.77M
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-1.81%
EPS Growth17.54%
CountryUK
Employees24,561
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,898,763,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£446.88Price Target Upside24.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.41B
Haleon PLC Business Overview & Revenue Model
Company Description
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health,...
How the Company Makes Money
Haleon makes money primarily by selling branded consumer healthcare products to retailers, wholesalers, pharmacies, and e-commerce customers. Revenue is generated from product sales across its major categories (e.g., oral health, pain relief, resp...
Haleon PLC Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: strong operational and margin progress (220 bps gross margin improvement), clear portfolio wins in Oral Health, meaningful cost-savings plans ($175–$200m) and strong emerging market execution (India, China). Offsetting this were persistent top-line and volume weaknesses, a weak cold & flu season (impacting the U.S. and other regions), channel inventory destocking and category-specific pressures (e.g., Nexium). Management signaled confidence in returning to medium-term growth targets but provided a conservative near-term organic guidance range (3%–5%) reflecting market uncertainty.Positive Updates
Organic Sales Growth Guidance
Guided organic sales growth of 3%–5% for FY2026, and reiterated medium-term ambition of 4%–6% despite FY2025 organic growth of 3%.
Negative Updates
U.S. Market Softness
U.S. sales were down approximately 0.5% in FY2025; company expects the U.S. cold and flu season to be below prior year in Q1 and recognized the U.S. remains a key area requiring improvement to hit medium-term targets.
Read all updates
Q4-2025 Updates
Positive
Negative
Organic Sales Growth Guidance
Guided organic sales growth of 3%–5% for FY2026, and reiterated medium-term ambition of 4%–6% despite FY2025 organic growth of 3%.
Read all positive updates
Company Guidance
Management guided 2026 organic sales growth of 3–5% (with a medium‑term ambition of 4–6%), noting FY25 organic growth was 3% (U.S. -0.5%) and that Q1 cold & flu is expected to be below a year ago but the U.S. should return to growth in 2026; they cited 220 basis points of gross‑margin improvement in 2025, $175–200m of gross savings from the reorganisation, and the ability to deliver high‑single‑digit operating growth at constant currency while still investing for growth, with 50–80 bps of supply‑chain productivity built into guidance; A&P rose ~7.5% (to ~20.5% of sales) and R&D +7.7%, working media was +12%, ROI improved mid‑single digits with ~75% coverage, and emerging markets showed strong metrics (India double‑digit growth, China e‑commerce ~40% of sales, Douyin >100% growth).Haleon PLC Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
63
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.03B | 11.23B | 11.30B | 10.86B | 9.54B |
| Gross Profit | 6.81B | 7.14B | 6.82B | 6.75B | 6.73B | 5.95B |
| EBITDA | 2.79B | 2.83B | 2.68B | 2.67B | 2.68B | 2.21B |
| Net Income | 1.52B | 1.67B | 1.44B | 1.05B | 1.06B | 1.39B |
Balance Sheet | ||||||
| Total Assets | 31.83B | 32.63B | 34.31B | 34.05B | 34.81B | 34.45B |
| Cash, Cash Equivalents and Short-Term Investments | 676.00M | 1.32B | 2.19B | 1.04B | 684.00M | 414.00M |
| Total Debt | 8.54B | 8.61B | 10.10B | 9.46B | 10.44B | 991.00M |
| Total Liabilities | 15.83B | 16.15B | 18.09B | 17.33B | 18.36B | 7.97B |
| Stockholders Equity | 15.94B | 16.43B | 16.17B | 16.61B | 16.33B | 26.36B |
Cash Flow | ||||||
| Free Cash Flow | 931.00M | 2.02B | 1.98B | 1.76B | 1.74B | 1.06B |
| Operating Cash Flow | 1.03B | 2.34B | 2.30B | 2.10B | 2.06B | 1.36B |
| Investing Cash Flow | -76.00M | -580.00M | 528.00M | -134.00M | -8.78B | -33.00M |
| Financing Cash Flow | -2.52B | -2.61B | -1.54B | -1.57B | 6.91B | -1.24B |
Haleon PLC Technical Analysis
Negative
358.60
Price Trends
378.11
Negative
371.70
Negative
360.78
Negative
Market Momentum
-5.18
Positive
42.79
Neutral
13.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HLN, the sentiment is Negative. The current price of 358.6 is below the 20-day moving average (MA) of 362.62, below the 50-day MA of 378.11, and below the 200-day MA of 360.78, indicating a bearish trend. The MACD of -5.18 indicates Positive momentum. The RSI at 42.79 is Neutral, neither overbought nor oversold. The STOCH value of 13.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HLN.
Haleon PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £31.60B | ― | 6.43% | 1.51% | -1.81% | 17.54% | |
60 Neutral | £76.14M | 2.80 | 7.82% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £94.56M | -4.82 | 206.44% | ― | 49.81% | 52.94% | |
45 Neutral | £664.92M | -7.21 | 409.00% | ― | 2.94% | -32.00% | |
45 Neutral | £24.63M | -11.67 | -51.21% | ― | -27.38% | -50.00% |
* Healthcare Sector Average
GB:HLN
Haleon PLC
350.80
-19.31
-5.22%
GB:AGY
Allergy Therapeutics
10.30
3.40
49.28%
GB:PXS
Provexis
1.03
0.45
79.20%
GB:STX
Shield Therapeutics
8.85
6.50
276.60%
GB:VLG
Venture Life
58.60
17.60
42.93%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
42.50
2.50
6.25%
Haleon PLC Corporate Events
Business Operations and StrategyStock Buyback
Haleon Cancels 8.7 Million Shares Under Ongoing Buyback Programme
Neutral
Apr 20, 2026
Haleon plc has repurchased 8,740,351 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026, with purchases executed across the London Stock Exchange and multiple alternative UK trading venues betwee...
Stock BuybackRegulatory Filings and Compliance
Haleon Cancels 7.7 Million Shares in Ongoing Buyback Programme
Positive
Apr 13, 2026
Haleon has continued executing its share buyback programme, purchasing 7,740,513 ordinary shares for cancellation between 7 and 10 April 2026 across multiple UK trading venues. Following these transactions, the company’s registered share cap...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Advances Share Buyback With 5.3 Million Share Cancellation
Positive
Apr 7, 2026
Haleon plc has repurchased 5,266,782 ordinary shares for cancellation under its ongoing share buyback programme, with purchases executed between 30 March and 2 April 2026 across the London Stock Exchange and multiple alternative trading venues. Fo...
Regulatory Filings and Compliance
Haleon Updates Share Capital and Voting Rights Total
Neutral
Apr 1, 2026
Haleon plc has confirmed that, as of 31 March 2026, it has 8,931,093,261 issued ordinary shares, of which 12,548,735 are held in treasury, leaving 8,918,544,526 shares carrying voting rights. This updated share capital and voting rights figure pro...
Stock Buyback
Haleon Cancels 8.9 Million Shares in Ongoing Buyback Programme
Positive
Mar 30, 2026
Haleon plc has executed a series of share repurchases, buying 8,939,706 ordinary shares for cancellation under the share buyback programme it launched earlier in March 2026. The transactions were carried out across multiple venues, including the L...
Executive/Board ChangesRegulatory Filings and Compliance
Haleon CEO McNamara Receives Vested Share Awards, Sells Portion to Cover Taxes
Neutral
Mar 24, 2026
Haleon plc has disclosed that Chief Executive Officer Brian McNamara received the vesting of share awards granted in March 2023 under the company’s Performance Share Plan and Deferred Annual Bonus Plan, including accrued dividends. The vesti...
Stock BuybackFinancial DisclosuresRegulatory Filings and Compliance
Haleon Cancels 7.8 Million Shares Under Ongoing Buyback Programme
Positive
Mar 23, 2026
Haleon has repurchased 7,833,121 ordinary shares for cancellation under its share buyback programme, with purchases executed between 16 and 20 March 2026 across venues including the London Stock Exchange and Cboe UK. Following these transactions, ...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Haleon Cuts Voting Share Count with March Buyback
Positive
Mar 16, 2026
Haleon plc has repurchased 2,749,486 ordinary shares for cancellation under the share buyback programme it launched on 12 March 2026, executing trades across the London Stock Exchange, Cboe venues and Aquis at volume-weighted average prices around...
Executive/Board Changes
Haleon grants long-term share awards to CEO and CFO under performance plans
Neutral
Mar 13, 2026
Haleon plc has granted conditional share awards to Chief Executive Officer Brian McNamara and Chief Financial Officer Dawn Allen under its Performance Share Plan and Deferred Annual Bonus Plan. The awards, totaling 1,813,680 shares for McNamara an...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Haleon Publishes 2025 Annual Report and Sets Date for Virtual 2026 AGM
Positive
Mar 13, 2026
Haleon has published its 2025 Annual Report and Accounts and Form 20-F, along with the notice of its 2026 Annual General Meeting, making these documents available on its corporate website and through relevant regulatory storage mechanisms in the U...
Business Operations and StrategyStock Buyback
Haleon Launches £500m Share Buyback to Cut Share Capital
Positive
Mar 12, 2026
Haleon plc has launched a share buyback programme of up to £500 million, in line with its capital allocation priorities and focus on delivering attractive returns to shareholders. The company has appointed HSBC Bank plc to execute the purchas...
Regulatory Filings and Compliance
Haleon Updates Total Voting Rights Following Share Capital Adjustment
Neutral
Mar 2, 2026
Haleon plc, a global consumer health specialist listed on the LSE and NYSE, develops and markets over-the-counter health products across oral health, vitamins and supplements, pain relief, respiratory and digestive health, and therapeutic skin cat...
DividendsFinancial Disclosures
Haleon lifts 2025 dividend on strong cash generation and earnings growth
Positive
Feb 25, 2026
Haleon plc, the consumer health group behind brands such as Sensodyne, Panadol and Advil, operates globally across oral care, pain relief, vitamins and other everyday health categories, targeting mass-market demand for over-the-counter products. T...
Regulatory Filings and Compliance
Haleon executives acquire shares under company reward plan
Neutral
Feb 12, 2026
Haleon plc has disclosed share transactions by senior executives Adrian Morris, General Counsel, and Jonathan Workman, President Europe, under the company’s Share Reward Plan. Both executives acquired partnership shares and received matching...
Regulatory Filings and Compliance
Haleon Confirms Voting Share Capital and Denominator for FCA Disclosure Rules
Neutral
Feb 2, 2026
Haleon plc has confirmed that as of 31 January 2026 it has 8,952,353,648 issued ordinary shares of £0.01 each, of which 45,557,120 are held in treasury, leaving 8,906,796,528 ordinary shares in issue with voting rights. The company stated tha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.